M. Klanova, L. H. Sehn, and I. Bence-bruckler, Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL, Blood, vol.133, issue.9, pp.919-926, 2019.

A. Korfel, T. Elter, and E. Thiel, Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas, Haematologica, vol.98, issue.3, pp.364-370, 2013.

N. Schmitz, S. Zeynalova, and M. Nickelsen, CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP, J Clin Oncol, vol.34, issue.26, pp.3150-3156, 2016.

D. Dobrovolsky, E. S. Wang, and S. Morrow, Bruton tyrosine kinase degradation as a therapeutic strategy for cancer, Blood, vol.133, issue.9, pp.952-961, 2019.

M. S. Davids, A. W. Roberts, and J. F. Seymour, Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma, J Clin Oncol, vol.35, issue.8, pp.826-833, 2017.

M. L. Wang, S. Rule, and P. Martin, Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, issue.6, pp.507-516, 2013.

P. Martin, K. Maddocks, and J. P. Leonard, Postibrutinib outcomes in patients with mantle cell lymphoma, Blood, vol.127, issue.12, pp.1559-1563, 2016.

D. Chiron, D. Liberto, M. Martin, and P. , Cellcycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer Discov, vol.4, issue.9, pp.1022-1035, 2014.

J. Krönkekr¨krönke, N. D. Udeshi, and A. Narla, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells, Science, vol.343, issue.6168, pp.301-305, 2014.